Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing Non-IPF Interstitial Lung Diseases

被引：0
|
作者：
Torrisi, S. [1 ,2 ,3 ]
Kahn, N. C. [1 ,2 ,3 ]
Waelscher, J. [1 ,2 ,3 ]
Sarmand, N. [1 ,2 ,3 ]
Polke, M. [1 ,2 ,3 ]
Heussel, C. [2 ,3 ,4 ]
Palmucci, S. [5 ]
Sambataro, G. [6 ]
Vancheri, C. [6 ]
Kreuter, M. [1 ,2 ,3 ]
机构：
[1] Heidelberg Univ, Ctr Interstitial & Rare Lung Dis, Thoraxklin, Heidelberg, Germany
[2] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany
[3] German Ctr Lung Res, Heidelberg, Germany
[4] Heidelberg Univ, Thoraxklin, Radiol, Heidelberg, Germany
[5] Univ Hosp, Dept Med Surg Sci & Adv Technol, Radiol Unit 1, Catania, Italy
[6] Univ Catania, Dept Clin & Expt Med, Reg Referral Ctr Rare Lung Dis, AOU Policlin Vittorio Emanuele, Catania, Italy
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4765
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Non-IPF Progressive Fibrosing Interstitial Lung Disease (PF-ILD): The Patient Journey
    Wijsenbeek, M.
    Kreuter, M.
    Fischer, A.
    Mounir, B.
    Zouad-Lejour, L.
    Wells, C. D.
    Quaresma, M.
    Cottin, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [12] Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed
    Wells, Athol
    LANCET RESPIRATORY MEDICINE, 2021, 9 (05): : 437 - 438
  • [13] The Addition of Antifibrotic Medications to Mycophenolate in the Treatment of Non-IPF Interstitial Lung Disease
    Baumgarten, D.
    Zhao, H.
    Criner, G. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [14] Antifibrotic therapy on progressive fibrotic lung disease non-IPF - a retrospective cohort
    Marques, M. Sousa De Sa
    Campainha, S.
    Nogueira, C.
    Marques, I
    Neves, S.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [15] Expanding horizons: lung transplantation for non-IPF interstitial lung diseases
    Citak, Sevinc
    Saribas, Ertan
    Halis, Ayse Nigar
    Alkilic, Fatma Feyza
    Cardak, Murat Ersin
    Vayvada, Mustafa
    Tasci, Ahmet Erdal
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [16] Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
    Amy L. Olson
    Toby M. Maher
    Valentina Acciai
    Baher Mounir
    Manuel Quaresma
    Leila Zouad-Lejour
    Christopher D. Wells
    Lou De Loureiro
    Advances in Therapy, 2020, 37 : 3292 - 3298
  • [17] Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA
    Olson, Amy L.
    Maher, Toby M.
    Acciai, Valentina
    Mounir, Baher
    Quaresma, Manuel
    Zouad-Lejour, Leila
    Wells, Christopher D.
    De Loureiro, Lou
    ADVANCES IN THERAPY, 2020, 37 (07) : 3292 - 3298
  • [18] Efficacy of Antifibrotic Treatments in Patients with Progressive Fibrosing Interstitial Lung Disease
    Sugino, K.
    Ono, H.
    Saito, M.
    Ando, M.
    Tsuboi, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [19] Incremental Healthcare Utilization and Cost Burden Associated with Non-IPF Chronic Fibrosing Interstitial Lung Disease (ILD) with a Progressive Phenotype
    Singer, D.
    Bengtson, L. G. S.
    Conoscenti, C. S.
    Anderson, A. J.
    Brekke, L.
    Shetty, S.
    Brown, K. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [20] Pulmonary rehabilitation in patients diagnosed with non-IPF-fibrosing interstitial lung disease receiving antifibrotic therapy
    Satar, Seher
    Sahin, Mustafa Engin
    Yesiloz, Zeynep
    Ergun, Pinar
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345